We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedical innovation. We also chat with health tech reporter Brittany Trang about the claims that two drug developers, Absci and Generate:Biomedicines, have made about the capabilities of their artificial intelligence technologies, and why some experts are skeptical.